The Food and Drug Administration today alerted health care providers to safety risks associated with cesium chloride, a mineral salt sometimes taken by cancer patients who seek alternative treatments. Reported adverse events included QT prolongation (a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm), low potassium, seizures, potentially lethal arrhythmias, fainting, cardiac arrest and death. FDA also said it intends to move cesium chloride to the category of substances that present significant safety risks in compounding. 

Related News Articles

Headline
The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices.
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Blog
We must address the racial, ethnic and socioeconomic disparities that increase the risk of negative perinatal outcomes for women of color.
Blog
AHA Executive Vice President Maryjane Wurth previews AHA’s Team Training Conference, where different interdisciplinary groups from diverse health care settings…
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Readmissions penalties for hospitals with the greatest share of dually eligible beneficiaries could fall by an estimated $22.4 million in fiscal year 2019,…